Please login to the form below

Not currently logged in
Email:
Password:

Tourette's syndrome

This page shows the latest Tourette's syndrome news and features for those working in and with pharma, biotech and healthcare.

Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder

Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder

up. The acquisition of Alder comes after Lundbeck bought  Abide Therapeutics for $400m earlier this year – adding mid-stage drug candidate ABX-1431 for Tourette’s syndrome – and last year’s ... $1b purchase of  Prexton Therapeutics and phase 2

Latest news

  • Lundbeck snaps up Abide Therapeutics for $400m Lundbeck snaps up Abide Therapeutics for $400m

    Also acquires its lead drug for Tourette’s syndrome. Danish drugmaker Lundbeck has moved to bolster its pipeline with a $400m deal to acquire Abide Therapeutics and its lead drug for ... ABX 1431 is in a phase 2a trial in Tourette’s syndrome –

  • Neurocrine bags FDA approval for first tardive dyskinesia drug Neurocrine bags FDA approval for first tardive dyskinesia drug

    Neurocrine says it is also expecting to report results for a trial of valbenazine in children with Tourette's syndrome next month, although an earlier study in adults failed to show ... If positive, Neurocrine is hoping to start a phase III trial in

  • FDA sets August review date for Teva's movement disorder drug FDA sets August review date for Teva's movement disorder drug

    Teva needs that kind of return, having forked out $3.5bn for SD-809's developer Auspex Pharma in 2015. ... Both companies are also exploring the use of their respective drugs to prevent tics associated with Tourette's syndrome.

  • FDA turns down Teva's Huntington's disease drug FDA turns down Teva's Huntington's disease drug

    Teva has been knocked back by an FDA decision not to approve deutetrabenazine, its candidate drug for chorea associated with Huntington's disease. ... and tics associated with Tourette's syndrome.

  • Neurocrine plans movement disorder drug filing in 2016 Neurocrine plans movement disorder drug filing in 2016

    Analysts at Nomura recently predicted that NBI-98854 could eventually become a $1.5bn product, even without a possible follow-up indication in Tourette's syndrome - and the announcement of the ... Neurocrine expects to complete its first phase Ib trial

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
The essential medicine list (EML) contains treatments considered to be the most effective and safe in targeting global health concerns. On 9 July 2019, the World Health Organization (WHO) published...
NICE
Evolution or revolution: the latest review of NICE methods
By Leela Barham...
PRO
Integrating patient reported outcomes into clinical trials
How capturing the patient voice is unlocking medicines’ commercial potential...

Infographics